期刊文献+

非负荷剂量替格瑞洛在择期PCI术前的使用 预览

Clinical Effectiveness and Safety Evaluation of Unloading Dose Ticagrelor before Delayed PCI in ACS Patients
在线阅读 下载PDF
收藏 分享 导出
摘要 目的评价急性冠脉综合征(ACS)患者行择期经皮冠状动脉介入治疗术(PCI)术前使用非负荷剂量替格瑞洛的疗效和安全性。方法前瞻性入选拟行择期PCI治疗的ACS患者,随机分为试验组148例和对照组139例(试验组首次给予替格瑞洛90mg,随后90mg每日两次维持,与之不同的是对照组替格瑞洛首次给药180mg负荷剂量,其余同试验组),两组均给予规范的冠心病药物治疗。观察两组住院期间及术后1年内主要心脑血管不良事件(MACCE)及出血的发生率。结果与对照组相比,试验组住院期间和术后1年内主要心脑血管不良事件发生率和出血事件的发生率没有统计学差异(P>0.05)。结论低中危缺血风险的急性冠脉综合征患者,在患者PCI术前使用负荷剂量替格瑞洛组与不使用组治疗效果基本一致,出血发生率相当。 Objective To evaluate the efficacy and safety of non-overload dose of tegrilol before elective percutaneous coronary intervention(PCI) in patients with acute coronary syndrome(ACS). Methods Prospectively selected ACS patients scheduled for PCI were randomly divided into experimental group(148 cases) and control group(139 cases). The experimental group was given tegrilol 90 mg for the first time and then maintained 90 mg twice a day. The difference was that the control group was given tegrilol 180 mg loading dose for the first time, and the rest were given standard drug treatment for coronary heart disease. The incidence of major cardiovascular and cerebrovascular adverse events(MACCE) and hemorrhage during hospitalization and 1 year after operation were observed.Results Compared with the control group, there was no significant difference in the incidence of major adverse cardiovascular and cerebrovascular events and hemorrhagic events during hospitalization and 1 year after operation between the experimental group and the control group(P>0.05). Conclusion For patients with acute coronary syndrome with low or medium risk of ischemia, the therapeutic effect of loading dose tegrilo group before PCI is basically the same as that of non-using group, and the incidence of bleeding is similar.
作者 杜胤龙 吴淳 董雪 朴福实 DU Yin-long;WU Chun;DONG Xue;PIAO Fu-shi(Peking University Shenzhen Hospital,Shenzhen Guangdong)
出处 《世界最新医学信息文摘(电子版)》 2019年第30期6-8,共3页 World Latest Medicine
关键词 替格瑞洛 非负荷剂量 择期介入治疗 Ticagrelor Unloading dose Delayed percutaneous coronary intervention
  • 相关文献

参考文献11

二级参考文献120

  • 1杨跃进.经皮冠状动脉介入治疗中无再流的诊断、治疗和预防[J].中华心血管病杂志,2004,32(7):662-664. 被引量:55
  • 2不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:1480
  • 3Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes[ J]. N Engl J Med, 2009, 361 ( 11 ): 1045-1057. DOI: 10. 1056/ NEJMou0904327. 被引量:1
  • 4Harem CW,Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) [ J ]. Eur Heart J, 2011 , 32 ( 23 ) : 2999-3054. DOI : 10.1093/eurheartj/ebr236. 被引量:1
  • 5O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infaretion: a repart of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[ J]. J Am Coll Cardiol,2013,61 (4) :e78-e140. DOI: 10. 1016/j. jacc. 2012.11. 019. 被引量:1
  • 6Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) [J]. Eur Heart J,2014,35(37) :2541-2619. DOI:10. 1093/eurheartj/ehu278. 被引量:1
  • 7Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines[ J ]. Circulation, 2014,130 ( 25 ) : e344-e426. DOI : 10. 1161/CIR. 0000000000000134,. 被引量:1
  • 8Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCBI single nucleotide polymorphisms on outcomes of treatment with tieagrelor versus clopidogrel for acute coronary syndromes:a genetic substndy of the PLATO trial [ J ]. Lancet, 2010. 376 (9749) : 1320-1328. DO1 : 10. 1016/S0140-6736 ( 10) 61274-3. 被引量:1
  • 9Li H, Butler K,Yang L, et al. Pharmacokinetics and tolerability of single and multiple doses of tieagrelor in healthy Chinese subjects : an open-label, sequential, two-cohort, single-centre study [ J]. Clin Drug Investig, 2012, 32 ( 2 ) : 87-97. DOI: 10. 2165/ 11595930.-000000000-00000. 被引量:1
  • 10Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome[ J]. Nat Rev Cardiol, 2015,1;2 ( 1 ) : 30-47. DOI : 10. 1038/nreardio. 2014. 156. 被引量:1

共引文献219

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈